Other · developed by Vir Biotechnology
VIR-1111 is a investigational agent studied in HIV-1 infection, given as a 1 mL subcutaneous injection in the deltoid area of the upper arm on Day 1 and Day 57.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04725877 | Phase 1 | HIV I Infection | Completed | VIR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
HIV I Infection
Updated Nov 1, 2026. Something wrong or missing? Report it on the VIR page.
See VIR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VIR catalysts and pipeline →